Magdalena Kegel,  —

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

Articles by Magdalena Kegel

Burden of Caring for Children with CF Is Heavier with Mothers, Study Finds

Mothers of young children with cystic fibrosis bear a heavier caregiving load than fathers, according to an Irish study. The research also showed that the caregiving burden increased as children grew older and when they became infected with the bacteria Pseudomonas aeruginosa. Although University College Dublin researchers identified circumstances that could affect…

GLPG2222 Plus Kalydeco Shows Positive Clinical Results in Phase 2 Trial, Galapagos Reports

Adding  investigational CFTR corrector GLPG2222 safely improved disease parameters in cystic fibrosis (CF) patients treated with Kalydeco (ivacaftor), reported the therapy’s Belgian developer, Galapagos, citing Phase 2 clinical trial data. The benefit of adding GLPG2222 was similar to that seen in an earlier study of a tezacaftor-Kalydeco combination, researchers said.

Spyryx Presents Data Ably Supporting SPX-101 as Potential Treatment for All CF Patients

Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate SPX-101, intended to improve lung function in all patients regardless of their underlying disease-causing mutation. The data, presented in four posters at the recent North American Cystic Fibrosis Conference (NACFC) in Indianapolis,…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.